All companies
ADMA Biologics logo

What smart money is saying about ADMA BiologicsUnited States flag

ADMA · Healthcare · Biotechnology · Market cap $4.26B

1 fund in our archive has pitched ADMA Biologics, most recently Renaissance IM Small Cap Growth in June 2025.

Company profile

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI
2
Reported positions
1
Bought
1
Sold
3
Letters

Position history

Between Q2 2025 and Q2 2026, 2 fund letters reported a position in ADMA Biologics, with 1 buy (opened or added) and 1 sell (trimmed or exited).

Fund letters reporting a position in ADMA Biologics, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261010
Q3 20251100
Q2 20250001

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 2 positions · 2 moves

Fund coverage · 1 thesis

  • ADMA Biologics is a commercial-stage biopharma company focused on plasma-based biologics for immune deficiencies and infectious disease prevention, with strong growth prospects and a target of $1 billion in revenue by 2030.

    Read the full thesis

Read every full thesis on ADMA Biologics

Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.

View plans→
Share this ledger